Intron A (interferon α-2b)

P3, N=586, Recruiting, University of Birmingham | Trial completion date: Feb 2028 --> Apr 2030 | Trial primary completion date: Aug 2026 --> Oct 2028

P=N/A, N=15, Not yet recruiting, Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital

This study demonstrates the versatility of in silico analysis to determine molecular function of large macromolecular complexes such as the spliceosome CC. Furthermore, our analysis indicates that therapeutic lowering of CC levels in colon cancer patients may enhance patient survival.

P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025

In addition, the results of ingenuity pathway analysis demonstrated the inhibition of T lymphocyte function, including differentiation, movement, and infiltration. Our results, for the first time, delineate the mechanisms underlying the immunotoxicity of BHPF in human lymphocytes.

P2, N=30, Suspended, Roswell Park Cancer Institute | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026

P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Aug 2025

P3, N=1673, Active, not recruiting, National Cancer Institute (NCI)

P2, N=88, Active, not recruiting, National Cancer Institute (NCI)

P3, N=427, Active, not recruiting, National Cancer Institute (NCI)

P2, N=30, Suspended, Roswell Park Cancer Institute | Trial completion date: Nov 2024 --> May 2024 | Trial primary completion date: Nov 2023 --> May 2024

P2, N=24, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting

In addition, the chimeric form had reduced cytotoxicity towards Vero cells and increased cell viability under viral load conditions compared with commercial IFN-a2b preparations. Analysis of the pharmacokinetic profile of ryIFN-ApoA-I after a single subcutaneous injection in mice showed a 1.8-fold increased half-life of the chimeric protein compared with ryIFN.

P3, N=1345, Active, not recruiting, National Cancer Institute (NCI)

P1, N=90, Recruiting, Mongolian National University of Medical Sciences

Intravesical nadofaragene firadenovec, administered once every three months, demonstrated a sustained durability of response in patients with BCG-unresponsive CIS±Ta/T1 papillary disease. Nadofaragene firadenovec represents a novel treatment option for BCG-unresponsive NMIBC with a favorable benefit-to-risk ratio. *All patients had passed 36 months at data cutoff on 09 September 2021.

CASE PRESENTATION: An 81-year-old female with a history of unprovoked DVT/PE on rivaroxaban presented to ED with progressive dyspnea on exertion for four months, a recent fever with a nonproductive cough, night sweats, and two subcutaneous nodules on her low back...These findings favored lupus panniculitis with a negative rheumatological workup, and a low dose of hydroxychloroquine was empirically started...The patient was started on R-CHOP... Though rare, lymphomatoid granulomatosis should be suspected for multiple pulmonary and cutaneous nodules, even in immunocompetent patients.

Considering their clinical potential and the early successful use of cytokines in cancer immunotherapy, such as interferon alpha-2b (IFNα-2b; IntronA) and IL-2 (Proleukin), cytokine-based therapeutics have been extensively evaluated in many follow-up clinical trials...In this review, we focus on the recent progress and competitive landscape in cytokine engineering strategies and preclinical/clinical therapeutics for cancer. In addition, aiming to promote engineered cytokine-based cancer immunotherapy, we present a profound discussion about the feasibility of recently developed methods in clinical medicine translation.

P1, N=8, Completed, Roswell Park Cancer Institute | Active, not recruiting --> Completed

P1/2, N=15, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2023 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025

Recurrence was not detected in any of the groups after one year follow up. Intralesional IFN-α 2b injection is an appropriate treatment choice for BCC.

P1, N=9, Completed, Roswell Park Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Feb 2023

No abstract available

GSLs following anti-CTLA4 and anti-PD1 antibody therapy in patients with melanoma were reported unusually. Reported cases ranged in grade from I to III and appeared manageable. Careful attention to these events and their reporting will be essential to better guide practice and management guidelines.

Interferon alfa-2b is efficacious for treating low-grade lymphomatoid granulomatosis and hence reducing progression to high-grade disease, whereas patients with high-grade lymphomatoid granulomatosis showed expected responses to chemotherapy. Uncontrolled immune regulation of Epstein-Barr virus is hypothesised to result in the emergence of low-grade disease after chemotherapy, for which treatment with interferon alfa-2b is efficacious.

P1, N=9, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=24 --> 9 | Trial completion date: May 2023 --> Feb 2024

P1/2, N=64, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended

P1, N=24, Suspended, Roswell Park Cancer Institute | Trial primary completion date: Aug 2022 --> May 2022

P1, N=24, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended

The deglycosylated CM (Ad-IFNα TERT-NHUC) produced a same degree of inhibition on the proliferation of KU7 cells (Fig 1). In conclusion, the cytotoxic effects of BSPs is independent of its status of glycosylation.

P1/2, N=64, Recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Nov 2021 --> Nov 2023

P2a, N=15, Completed, Roswell Park Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> Aug 2021

P1/2, N=64, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2022 --> Nov 2022

Nadofaragene firadenovec was well tolerated and demonstrates durability of response in pts with HG Ta/T1, BCG-unresponsive NMIBC in 24 mos follow-up after first intravesical treatment. Clinical trial information: NCT02773849.

Nadofaragene firadenovec instilled intravesically once every 3 mos demonstrates sustained durability of response with longer follow-up in pts with HG, BCG-unresponsive NMIBC. Clinical trial information: NCT02773849.

Secondary analysis of the prospective, multicenter phase 3 nadofaragene firadenovec trial in BCG-unresponsive NMIBC indicates a role for assaying baseline and on-treatment Ab titers. A combination of Ab titer and fold-change levels can potentially predict response to this novel therapeutic in a patient population with urgent unmet clinical need.

P1/2, N=64, Recruiting, Roswell Park Cancer Institute | N=44 --> 64 | Trial completion date: Sep 2021 --> Apr 2022

Both adjuvant toripalimab and HDI therapy improve RFS of mucosal melanoma . Toripalimab shows longer RFS in PDL1 (+) subgroup and better tolerance than HDI.

Conclusions Neoadjuvant concurrent HDI and pembrolizumab demonstrated promising clinical activity despite high rates of treatment discontinuation. pCR is a prognostic indicator.

P1/2, N=60, Recruiting, BriaCell Therapeutics Corporation | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022

P2a, N=23, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2023 --> Feb 2024 | Trial primary completion date: Apr 2022 --> Feb 2023

P2a, N=15, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2022 --> Dec 2021 | Trial primary completion date: Apr 2022 --> Dec 2020